These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Nifedipine-induced parotitis: a hypersensitivity reaction. Massimo C; Sebastianelli G; Noera G Am J Cardiol; 1988 Apr; 61(10):874. PubMed ID: 3354462 [No Abstract] [Full Text] [Related]
25. Adverse reactions with long-term use of phenylbutazone and oxyphenbutazone. Sperling IL Lancet; 1969 Sep; 2(7619):535-7. PubMed ID: 4184850 [No Abstract] [Full Text] [Related]
30. Double-blind clinical trial of protacine versus oxyphenbutazone in rheumatic disorders. Loizzi P; Pipitone V; Bignamini AA Pharmatherapeutica; 1980; 2(5):285-92. PubMed ID: 7001487 [TBL] [Abstract][Full Text] [Related]
31. Ulcer of the cecum during oxyphenbutazone (tandearil) therapy. Debenham GP Can Med Assoc J; 1966 May; 94(22):1182-4. PubMed ID: 5934387 [No Abstract] [Full Text] [Related]
32. Thrombocytopenia and L.E. cells after oxyphenbutazone. Handley AJ Lancet; 1971 Jan; 1(7692):245-6. PubMed ID: 4099912 [No Abstract] [Full Text] [Related]
38. Withdrawal of oxyphenbutazone: what about phenylbutazone? Biron P CMAJ; 1986 May; 134(10):1119-20. PubMed ID: 3697857 [No Abstract] [Full Text] [Related]
39. Phenylbutazone, oxyphenbutazone and aplastic anaemia. Böttiger LE Br Med J; 1977 Jul; 2(6081):265. PubMed ID: 884472 [No Abstract] [Full Text] [Related]
40. Phenylbutazone and oxyphenbutazone: time to call a halt. Drug Ther Bull; 1984 Jan; 22(2):5-6. PubMed ID: 6692755 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]